High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.

Author: BandaruSrinivas, DunnaNageswara Rao, GirdharAmandeep, HussainTajamul, KandulaVenkatesh, NayarisseriAnuraj, PuduthaAmareshwari

Paper Details 
Original Abstract of the Article :
Clinical evidence shows that dual inhibition of kinases as well angiogenesis provides ideal therapeutic option in the treatment of medullary thyroid carcinoma (MTC) than inhibiting either of these with the events separately. Although treatment with dual inhibitors has shown good clinical responses i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.7314/apjcp.2015.16.16.7089

データ提供:米国国立医学図書館(NLM)

Dual Inhibition of Kinases and Angiogenesis: A New Oasis in the Desert of Medullary Thyroid Carcinoma Treatment

Medullary thyroid carcinoma (MTC), a type of cancer affecting the thyroid gland, presents significant challenges for treatment. This research explores the potential of dual inhibitors targeting both RET and VEGFR2 kinases for a more effective approach to MTC treatment. The study notes that while dual inhibitors have shown promising results in clinical trials, they are often associated with severe side effects. The researchers aim to identify high-affinity dual inhibitors with improved safety profiles, potentially offering a more balanced solution for MTC patients.

A New Path in the Desert of MTC Treatment

MTC, like a desert mirage, can be difficult to treat effectively. This research aims to find a new oasis by exploring the potential of dual inhibitors that target both RET and VEGFR2 kinases. The researchers hope to identify compounds with better safety profiles, offering a more effective and less toxic treatment for MTC patients.

The Quest for a Balanced Approach in the Desert of Cancer

Cancer treatment, like navigating a vast desert, often involves trade-offs between effectiveness and toxicity. This research seeks a more balanced approach, identifying dual inhibitors that target both kinases and angiogenesis with greater efficacy and fewer side effects. Their findings could pave the way for more effective and well-tolerated treatments for MTC patients.

Dr.Camel's Conclusion

This research offers a promising avenue for improving the treatment of MTC. By identifying high-affinity dual inhibitors with improved safety profiles, the researchers hold out the possibility of a more effective and less toxic treatment option for MTC patients. Their findings could lead to a significant shift in the treatment landscape for this complex disease, offering a more balanced approach to managing MTC and improving the lives of patients.
Date :
  1. Date Completed 2016-08-16
  2. Date Revised 2022-03-25
Further Info :

Pubmed ID

26514495

DOI: Digital Object Identifier

10.7314/apjcp.2015.16.16.7089

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.